Immune Checkpoint Blockade Combined with AbnobaViscum® Therapy Is Linked to Improved Survival in Advanced or Metastatic Non-Small-Cell Lung Cancer Patients: A Registry Study in Accordance with the ESMO Guidance for Reporting Real-World Evidence

DSpace Repositorium (Manakin basiert)

Immune Checkpoint Blockade Combined with AbnobaViscum® Therapy Is Linked to Improved Survival in Advanced or Metastatic Non-Small-Cell Lung Cancer Patients: A Registry Study in Accordance with the ESMO Guidance for Reporting Real-World Evidence

Autor(en): Schad, Friedemann; Thronicke, Anja; Hofheinz, Ralf-Dieter; Klein, Reinhild; Grabowski, Patricia; Oei, Shiao Li; Wuestefeld, Hannah; Grah, Christian
Tübinger Autor(en):
Klein, Reinhild
Erschienen in: Pharmaceuticals (2024), Bd. 17 (12), Article 1713
Verlagsangabe: Basel : Mdpi
Sprache: Englisch
Referenz zum Volltext: http://dx.doi.org/10.3390/ph17121713
ISSN: 1424-8247
DDC-Klassifikation: 540 - Chemie
610 - Medizin, Gesundheit
Dokumentart: Wissenschaftlicher Artikel
Zur Langanzeige

Das Dokument erscheint in: